Assembly Biosciences, INC.: management transactions · United States · SEC (Form 4)

About Assembly Biosciences, INC.

Assembly Biosciences, Inc. (NASDAQ: ASMB) is a United States-based biotechnology company headquartered in South San Francisco, California. The company was incorporated in Delaware in October 2005, originally as South Island Biosciences, Inc., later operating as Ventrus Biosciences before adopting the Assembly Biosciences name in 2014 following a merger with Assembly Pharmaceuticals. For investors, this is best characterized as a clinical-stage biotech story: value creation depends primarily on research execution, clinical readouts, partnering activity, and regulatory progress rather than commercial product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001426800/000119312526115992/asmb-20251231.htm?utm_source=openai)) Assembly Biosciences develops innovative therapeutics for serious viral diseases, with a pipeline concentrated on herpesviruses and hepatitis-related infections. Its 2024 Annual Report states that the company’s clinical-stage portfolio includes two helicase-primase inhibitors for recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a next-generation capsid assembly modulator for hepatitis B virus (HBV), and a novel oral broad-spectrum non-nucleoside polymerase inhibitor aimed at transplant-related herpesviruses. This mix gives ASMB a focused, specialist profile rather than a broad platform biotech model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1426800/000095017025057331/asmb_-_2024_annual_repor.pdf)) In competitive terms, the company targets areas of significant unmet medical need where differentiation can come from mechanism of action, durability, oral convenience, and tolerability. In recurrent genital herpes, Assembly is aiming to deliver long-acting oral antivirals that could improve adherence and clinical control compared with more traditional approaches. In HBV and HDV, it is pursuing next-generation antiviral mechanisms in disease areas where current treatment options remain limited and where improved viral suppression is still a major goal. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1426800/000095017025057331/asmb_-_2024_annual_repor.pdf)) Recent news has been material. In 2025, Assembly reported positive Phase 1b results for ABI-4334 in chronic hepatitis B, highlighting favorable safety and pharmacokinetics supportive of once-daily oral dosing. In December 2025, the company disclosed positive interim Phase 1b data for ABI-1179 and ABI-5366 in recurrent genital herpes, including strong reductions in viral shedding and lesion rates. Most importantly, Gilead Sciences exercised its option to exclusively license Assembly’s herpes simplex virus helicase-primase inhibitor programs, including ABI-1179 and ABI-5366, a meaningful external validation of the platform and an important strategic milestone. ([investor.assemblybio.com](https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-positive-topline-results-phase-1b?utm_source=openai)) The company is listed on NASDAQ in the United States and remains highly dependent on pipeline milestones. Its geographic footprint is concentrated in California, and its investment case is driven by clinical data, business development, and the ability to convert scientific promise into partner-backed or eventually commercial value. For French-speaking investors, ASMB is a high-risk, high-upside specialist antiviral biotech with clear catalyst sensitivity.